OncoNano Medicine, Inc. today announced that it has been awarded $15.4m (£12.6m) from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance ONM-500, one of OncoNano’s innovative oncology product candidates.
Zogenix has agreed to acquire Modis Therapeutics, a California-based biopharma company focused on developing disease-modifying therapies for rare genetic diseases, in a cash-cum-stock deal worth over $400m (£325.72m).
ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), and Freenome, a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw, announced that they have entered a biomarker development collaboration in which ADC Therapeutics will use Freenome’s platform to identify patients who are most likely to respond to treatment with ADCT-402 (loncastuximab tesirine).
Cantargia and BioWa have signed an extension of the licence agreement around the BioWa proprietary POTELLIGENT technology for production of Cantargia’s antibody drug candidate CAN04, which gives Cantargia broader rights to use the technology.
Gilead Sciences has finalised its 10-year global research and development deal, worth up to $5.05bn (£4.11bn), with Belgium-based Galapagos following regulatory clearances.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the completion of a $53m (£43.38m) Series C financing.
US-based Oncorus has raised $79.5m (£65.56m) in a Series B financing round co-led by Cowen Healthcare Investments and Perceptive Advisors.
Graybug Vision, a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), today announced the securing of an $80 million (£66m) Series C financing.
Siamab Therapeutics, a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202m (£166m) with an undisclosed, large commercial-stage biopharmaceutical company under which such company will develop and commercialise antibody-based products targeting a tumor-associated carbohydrate antigen (TACA) identified by Siamab’s proprietary TACA discovery platform.
Caisse de dépôt et placement du Québec (CDPQ), a Canadian long-term institutional investor, has agreed to make a minority investment of $500m (£413.8m) in Mexican pharmaceutical company Sanfer.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.